DOI: 10.25881/20728255_2022_17_3_142

Authors

Nguen V.T.1, Bromberg B.B.1, Novikova M.V.1, Prosvetov V.A.1, Korzhuk M.S.1, Demko A.E.2, Eselevich R.V.1, Surov D.A.1

1 S.M. Kirov Military medical academy, St. Petersburg

2 Research Institute Of Emergency Medecine named after I.I. Djanelidzе, St. Petersburg

Abstract

The article presents a clinical observation of a patient with an aggressive (proliferative activity index Ki67 — 70%) form of small intestine cancer (SIC). After the diagnosis was established in 2017, the patient underwent radical (April 2017) and cytoreductive (February 2019) surgical interventions with postoperative intra-abdominal normothermic chemoperfusion at the oncology center, as well as systemic chemotherapy for 3 years. Despite the complex treatment, due to the unfavorable biological properties of the tumor, the progression of the oncological process in the form of peritoneal carcinomatosis was stated. Against the background of ongoing systemic chemotherapy, the patient developed life-threatening complications — a violation of the small intestine patency of carcinomatous genesis and necrosis of recurrent tumor nodes. The severity of the clinical situation determined the necessity of using cytoreductive technologies in the provision of surgical care in a multidisciplinary emergency hospital.

The article describes in detail the tactics of complex treatment of a patient with advanced complicated small intestine cancer, discusses the indications for surgical treatment, its volume and stages, as well as evaluates immediate and long-term outcomes.

Keywords: small intestine cancer, peritoneal carcinomatosis, peritoneal carcinomatosis index, tumor necrosis, intestinal obstruction, cytoreductive surgery, heperthermic intra-abdominal chemoperfusion.

References

1. Howe JR, et al. Adenocarcinoma of the small bowel: Review of the National Cancer Data Base, 1985-1995. Cancer. 1999; 86(12): 2693-2706.

2. DeVita VT, Lawrence TS, Rosenberg SA. DeVita, Hellman, and Rosenberg’s cancer: principles & practice of oncology. 2019.

3. Dabaja BS, et al. Adenocarcinoma of the small bowel: Presentation, prognostic factors, and outcome of 217 patients. Cancer. 2004; 101(3): 518-526. doi: 10.1002/cncr. 20404.

4. Legué LM, et al. Trends in incidence, treatment and survival of small bowel adenocarcinomas between 1999 and 2013: a population-based study in The Netherlands. Acta Oncol. 2016; 55(9-10): 1183-1189. doi: 10.1080/0284186X. 2016.1182211.

5. Frost DB, Mercado PD, Tyrell JS. Small bowel cancer: A 30-year review. Ann. Surg. Oncol. 1994; 1(4): 290-295. doi: 10.1007/BF02303567.

6. Cordova-Delgado M, et al. Case Report: Molecular Features and Treatment Options for Small Bowel Adenocarcinoma. Front. Oncol. 2021; 11: 593561. doi: 10.3389/fonc.2021.593561.

7. Locher C, et al. Small bowel adenocarcinoma: French intergroup clinical practice guidelines for diagnosis, treatments and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO). Dig. Liver Dis. 2018; 50(1): 15-19. doi: 10.1016/j.dld.2017.09.123.

8. Benson AB, et al. Small Bowel Adenocarcinoma, Version 1.2020, NCCN Clinical Practice Guidelines in Oncology. J. Natl. Compr. Canc. Netw. National Comprehensive Cancer Network. 2019; 17(9): 1109-1133. doi: 10.6004/ jnccn.2019.0043.

9. Raghav K, Overman MJ. Small bowel adenocarcinomas — existing evidence and evolving paradigms. Nat. Rev. Clin. Oncol. 2013; 10(9): 534-544. doi: 10.1038/nrclinonc.2013.132.

10. Grinev MV. Tsitoreduktivnaya khirurgiya: (na modeli lecheniya kolorektal’nogo raka IV stadii). St. Petersburg: Gippokrat; 2003. 92 p. (In Russ).

11. Aparicio T, et al. Small bowel adenocarcinoma: Epidemiology, risk factors, diagnosis and treatment. Dig. Liver Dis. 2014; 46(2): 97-104. doi: 10.1016/j.dld.2013.04.013.

12. The BIG-RENAPE Group, et al. Cytoreductive Surgery Plus Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Metastases From a Small Bowel Adenocarcinoma: Multi-Institutional Experience. Ann. Surg. Oncol. 2018; 25(5): 1184-1192. doi: 10.1245/s10434-018-6369-x.

13. Li LT, et al. Ki67 is a promising molecular target in the diagnosis of cancer (Review). Mol. Med. Rep. 2015; 11(3): 1566-1572. doi: 10.3892/mmr.2014.2914.

14. Belyaev AM, et al. Сomplex treatment of peritoneal carcinomatosis from colorectal cancer. Medlin. Rossiiskii Biomeditsinskii Zhurnal. 2011; 12: 185-201. (In Russ).

15. Belyaev AM. Tsitoreduktivnye operatsii i gipertermicheskaya vnutribryushinnaya khimioterapiya v kompleksnom lechenii rasprostranennykh form intraabdominal’nogo raka. [dissertation] Moscow; 2004. (In Russ).

16. Belyaeva OA. Khimioperfuzionnoe lechenie kantseromatoza bryushnoi polosti / O.A. Belyaeva, et al. St.-petersburg, 2016. 146 p. (In Russ).]

17. Ionova TI, et al. Prakticheskie rekomendatsii po otsenke kachestva zhizni u onkologicheskikh bol’nykh. Zlokachestvennye opukholi: Prakticheskie rekomendatsii RUSSCO≠3s2. 2017; (7): 586–891. (In Russ).]doi: 10.18027 / 2224–5057–2017–7–3s2–586–591.

For citation

Nguen V.T., Bromberg B.B., Novikova M.V., Prosvetov V.A., Korzhuk M.S., Demko A.E., Eselevich R.V., Surov D.A. Using two-stage cytoreductive surgery in a patient with complicated progressive small intestinal cancer. Bulletin of Pirogov National Medical & Surgical Center. 2022;17(3):142-147. (In Russ.) https://doi.org/10.25881/20728255_2022_17_3_142